Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.
Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the bla(CMY) genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.
Doi
Yohei
Y
Division of Infectious Diseases, University of Pittsburgh Medical Center, 3550 Terrace Street, Pittsburgh, PA 15261, USA. yod4@pitt.edu
Paterson
David L
DL
Adams-Haduch
Jennifer M
JM
Sidjabat
Hanna E
HE
O'Keefe
Alexandra
A
Endimiani
Andrea
A
Bonomo
Robert A
RA
D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000077723:Cefepime; D002511:Cephalosporins / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology* / Q000235:genetics; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D017386:Sequence Homology, Amino Acid; D001618:beta-Lactamases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077723:Cefepime; C103022:beta-lactamase CMY-2; D001618:beta-Lactamases